PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rifaximin 200mg tablets - Travellers diarrhoea

PAD Profile : Rifaximin 200mg tablets - Travellers diarrhoea

Keywords :
antibiotic, antibacterial
Brand Names Include :
Xifaxanta

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Important
Formulations :
  • Not Specified
Important Information :
STAND-BY or PREVENTATIVE treatment is not currently recommended in the NHS Surrey Management of Infection Guidelines. it is difficult for travellers to distinguish between invasive and non-invasive diarrhoea, the overall usefulness of rifaximin as empiric self-treatment remains to be determined. Stand-by treatment of this nature should not be prescribed on the NHS but a private prescription may be issued if appropriate
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
24 October 2012
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
STAND-BY or PREVENTATIVE treatment is not currently recommended in the NHS Surrey Management of Infection Guidelines. it is difficult for travellers to distinguish between invasive and non-invasive diarrhoea, the overall usefulness of rifaximin as empiric self-treatment remains to be determined. Stand-by treatment of this nature should not be prescribed on the NHS but a private prescription may be issued if appropriate

Associated BNF Codes

05. Infections
05.01.07. Some other antibacterials
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More